Neoadjuvant endocrine therapy of breast cancer: Which patients would benefit and what are the advantages?

Breast Cancer

Volumn 18, Issue 2, 2011, Pages 85-91

  Takei, Hiroyuki ^a   Kurosumi, Masafumi ^a   Yoshida, Takashi ^a   Hayashi, Yuji ^a   Higuchi, Toru ^a   Uchida, Sayaka ^a   Ninomiya, Jun ^a   Oba, Hanako ^a   Inoue, Kenichi ^a   Nagai, Shigenori ^a   Tabei, Toshio ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

Aromatase inhibitor; Neoadjuvant chemotherapy; Neoadjuvant endocrine therapy; Tamoxifen; Tumor response

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; DOXORUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; GONADORELIN DERIVATIVE; KI 67 ANTIGEN; LETROZOLE; PACLITAXEL; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; DRUG INDICATION; DRUG RESPONSE; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT PLANNING; TUMOR VOLUME;

AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; POSTMENOPAUSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 79956343766     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-010-0239-0     Document Type: Article

References (31)

1. P Rastogi SJ Anderson HD Bear CE Geyer MS Kahlenberg A Robidoux, et al. 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 778 785 18258986 10.1200/JCO.2007.15.0235 (Pubitemid 351264391)
2. JG van Nes H Putter JP Julien M Tubiana-Hulin M van de Vijver J Bogaerts, et al. 2009 Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902 Breast Cancer Res Treat 115 101 113 18484198 10.1007/s10549-008- 0050-1
3. NS Goldstein D Decker D Severson S Schell F Vicini J Margolis, et al. 2007 Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy Cancer 110 1687 1696 17722109 10.1002/cncr.22981 1:CAS:528:DC%2BD2sXht1GksLzN (Pubitemid 47557293)
4. VF Semiglazov VV Semiglazov GA Dashyan EK Ziltsova VG Ivanov AA Bozhok, et al. 2007 Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer Cancer. 110 244 254 17538978 10.1002/cncr.22789 1:CAS:528: DC%2BD2sXos1yrsbk%3D (Pubitemid 47121883)
5. JG Klijn LV Beex L Mauriac JA van Zijl C Veyret J Wildiers, et al. 2000 Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study J Natl Cancer Inst 92 903 911 10841825 10.1093/jnci/92.11.903 1:CAS:528:DC%2BD3cXksF2qur4%3D (Pubitemid 30429190)
6. R Torrisi V Bagnardi G Pruneri R Ghisini L Bottiglieri E Magni, et al. 2007 Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer Br J Cancer 97 802 808 17712311 10.1038/sj.bjc.6603947 1:CAS:528:DC%2BD2sXhtVWksLzN (Pubitemid 47396292)
7. Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment. http://clinicaltrials.gov/ct2/show/ NCT00605267.
8. PM Hoff V Valero AU Buzdar SE Singletary RL Theriault D Booser, et al. 2000 Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy Cancer 88 2054 2060 10813717 10.1002/(SICI)1097-0142(20000501) 88:9<2054::AID-CNCR11>3.0.CO;2-J 1:CAS:528:DC%2BD3cXjtF2murk%3D (Pubitemid 30233207)
9. S Akashi-Tanaka M Omatsu C Shimizu M Ando K Terada T Shien, et al. 2007 Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy Breast. 16 482 488 17418576 10.1016/j.breast.2007.02.003 (Pubitemid 47491605)
10. D Hind L Wyld MW Reed 2007 Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review Br J Cancer 96 1025 1029 17285133 10.1038/sj.bjc.6603600 1:CAS:528: DC%2BD2sXjsleks74%3D (Pubitemid 46608304)
11. JM Dixon L Renshaw C Bellamy M Stuart G Hoctin-Boes WR Miller 2000 The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study Clin Cancer Res 6 2229 2235 10873072 1:CAS:528:DC%2BD3cXksVGhsrk%3D (Pubitemid 30399188)
12. Renshow L, Murray J, Young O, Cameron D, Miller WR, Dixon JM. Is there an optimal duration of neoadjuvant letrozole therapy? Breast Cancer Res Treat. 2004;88:S36 (Abstract #405).
13. Llombart A, Galan A, Fuster C, Buch E, Caranana V, Rodriguez-Lescure A, et al. Phase II trial with letrozole (2.5 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Eur J Cancer Suppl. 2006;4:154 (Abstract #362).
14. M Tubiana-Hulin V Becette I Bieche L Mauriac G Romieu F Bibeau, et al. 2007 Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial Anticancer Res 27 2689 2696 17695434 1:CAS:528:DC%2BD2sXpvFChtr8%3D (Pubitemid 47227984)
15. Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Jänicke F, Bastert G, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer. 2008;8:62.
16. H Takei K Suemasu K Inoue T Saito K Okubo J Koh, et al. 2008 Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03) Breast Cancer Res Treat 107 87 94 18043897 10.1007/s10549-007-9529-4 1:CAS:528:DC%2BD2sXhtlGrtbvN (Pubitemid 350179589)
17. B Mlineritsch C Tausch C Singer G Luschin-Ebengreuth R Jakesz F Ploner, et al. 2008 Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17) Breast Cancer Res Treat 112 203 213 18158620 10.1007/s10549-007-9843-x 1:CAS:528: DC%2BD1cXhtFOjtrnP
18. A Barnadas M Gil S González I Tusquets M Muñoz A Arcusa, et al. 2009 Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial Br J Cancer 100 442 449 19156139 10.1038/sj.bjc.6604868 1:CAS:528:DC%2BD1MXhsFektrs%3D
19. G Mustacchi M Mansutti C Sacco S Barni A Farris M Cazzaniga, et al. 2009 Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study Ann Oncol 20 655 659 19150936 10.1093/annonc/mdn687 1:STN:280:DC%2BD1M3jt1eqsA%3D%3D
20. W Eiermann S Paepke J Appfelstaedt A Llombart-Cussac J Eremin J Vinholes Letrozole Neo-Adjuvant Breast Cancer Study Group, et al. 2001 Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study Ann Oncol. 12 1527 1532 11822750 10.1023/A:1013128213451 1:STN:280:DC%2BD38%2FptlGisw%3D%3D (Pubitemid 34065880)
21. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, IMPACT Trialists Group, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108-16. (Pubitemid 46224019)
22. Semiglazov V, Kletsel A, Semiglazov V, Zhiltzova E, Ivanov V, Dashyan G, et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). Proc Am Soc Clin Oncol. 2005;23:11s (Abstract #530).
23. L Cataliotti AU Buzdar S Noguchi J Bines Y Takatsuka K Petrakova, et al. 2006 Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial Cancer. 106 2095 2103 16598749 10.1002/cncr.21872 1:CAS:528:DC%2BD28XkvFOntrc%3D (Pubitemid 43673229)
24. M Kurosumi Y Takatsuka T Watanabe S Imoto H Inaji H Tsuda, et al. 2008 Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial J Cancer Res Clin Oncol 134 715 722 18075758 10.1007/s00432-007-0343-5 1:CAS:528:DC%2BD1cXksVKrurc%3D
25. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
26. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer. 47 207 214 7459811 10.1002/1097-0142(19810101)47: 1<207::AID-CNCR2820470134>3.0.CO;2-6 1:STN:280:DyaL3M7htFOltw%3D%3D (Pubitemid 11167383)
27. M Kurosumi S Akashi-Tanaka F Akiyama Y Komoike H Mukai S Nakamura, et al. 2008 Committee for Production of Histopathological Criteria for Assessment of Therapeutic Response of Japanese Breast Cancer Society: histopathological criteria for assessment of therapeutic response in breast cancer (2007 version) Breast Cancer. 15 5 7 18224386 10.1007/s12282-007-0016-x
28. DM Sataloff BA Mason AJ Prestipino UL Seinige CP Lieber Z Baloch 1995 Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome J Am Coll Surg 180 297 306 7874340 1:STN:280:DyaK2M7nvFemsQ%3D%3D
29. M Dowsett SR Ebbs M Dixon A Skene C Griffith I Boeddinghaus, et al. 2005 Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer-A study form the IMPACT trialists J Clin Oncol 23 2477 2492 15767642 10.1200/JCO.2005.07.559 1:CAS:528:DC%2BD2MXjvVyktLw%3D (Pubitemid 47050838)
30. M Dowsett IE Smith SR Ebbs JM Dixon A Skene R A'Hern, et al. 2007 Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 167 170 17228000 10.1093/jnci/djk020 1:CAS:528:DC%2BD2sXhvVOhtbc%3D
31. MJ Ellis Y Tao J Luo R A'Hern DB Evance AS Bhatnagar, et al. 2008 Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J Natl Cancer Inst 100 1380 1388 18812550 10.1093/jnci/djn309 1:CAS:528:DC%2BD1cXht1Sitb7F